Related Experiment Videos
Factors contributing to ribavirin-induced anemia
Hideyuki Nomura1, Hironori Tanimoto, Eiji Kajiwara
1Department of Internal Medicine, Shin-Kokura Hospital, Kitakyushu, Fukuoka, Japan. h-nomura@shin-kokura.gr.jp
Journal of Gastroenterology and Hepatology
|October 16, 2004
Summary
Certain patients require careful monitoring during interferon and ribavirin therapy for chronic hepatitis C. Female patients, those over 60, and individuals on higher ribavirin doses are at increased risk for anemia.
Area of Science:
- Hepatology
- Pharmacology
- Hematology
Background:
- Hepatitis C treatment with interferon and ribavirin can cause hemolytic anemia.
- Identifying factors contributing to ribavirin-induced anemia is crucial for patient safety.
Purpose of the Study:
- To identify risk factors for developing anemia during combination therapy for chronic hepatitis C.
- To establish criteria for monitoring patients at higher risk.
Main Methods:
- Eighty-eight chronic hepatitis C patients received interferon-alpha-2b and ribavirin.
- Anemia was defined as hemoglobin <10 g/dL.
- Risk factors including age, sex, and ribavirin dosage were analyzed.
Main Results:
- Anemia occurred in 20.5% of patients.
- A hemoglobin decrease of >=2 g/dL by week 2 predicted more severe anemia.
- Female sex, age >=60, and ribavirin dose >=12 mg/kg were significant risk factors.
Conclusions:
- Careful monitoring is advised for elderly, female, and high-dose ribavirin patients.
- Patients with a >=2 g/dL hemoglobin drop by week 2 need close observation.
- Early identification of risk factors can prevent severe anemia during treatment.